TuisABUS • NASDAQ
add
Arbutus Biopharma Corp
Vorige sluiting
$4,12
Dagwisseling
$4,11 - $4,19
Jaarwisseling
$1,69 - $4,72
Markkapitalisasie
783,45 m USD
Gemiddelde volume
1,31 m
P/V-verhouding
-
Dividend-opbrengs
-
Primêre beurs
NASDAQ
Marknuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
(USD) | Jun. 2024info | J/J-verandering |
---|---|---|
Inkomste | 1,73 m | -62,89% |
Bedryfskoste | 21,98 m | -3,15% |
Netto inkomste | -19,80 m | -15,81% |
Netto winsgrens | -1,15 k | -212,06% |
Wins per aandeel | -0,15 | -14,22% |
EBITDA | -21,02 m | -12,51% |
Effektiewe belastingkoers | — | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
(USD) | Jun. 2024info | J/J-verandering |
---|---|---|
Kontant en korttermynbeleggings | 141,99 m | -6,88% |
Totale bates | 160,04 m | -9,49% |
Totale aanspreeklikheid | 37,59 m | -10,78% |
Totale ekwiteit | 122,45 m | — |
Uitstaande aandele | 188,78 m | — |
Prys om te bespreek | 6,34 | — |
Opbrengs op bates | -34,43% | — |
Opbrengs op kapitaal | -42,30% | — |
Kontantvloei
Netto kontantverandering
(USD) | Jun. 2024info | J/J-verandering |
---|---|---|
Netto inkomste | -19,80 m | -15,81% |
Kontant van bedrywe | -14,50 m | 25,84% |
Kontant van beleggings | 9,83 m | 582,10% |
Kontant van finansiering | 24,37 m | 413,92% |
Netto kontantverandering | 19,69 m | 247,17% |
Beskikbare kontantvloei | -7,10 m | 31,18% |
Meer oor
Arbutus Biopharma Corporation is a publicly traded Canadian biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection.
It is headquartered in Warminster, Pennsylvania. The company was formerly known as Tekmira, which was spun out of Inex Pharmaceuticals in 2007. Wikipedia
Gestig
2007
Webwerf
Werknemers
73